Progenics Pharma Cash Flow - Quarterly (NASDAQ:PGNX)

Add to My Stocks
$8.54 $0.04 (0.47%) PGNX stock closing price Jun 19, 2018 (Closing)

The Progenics Pharma cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Progenics Pharma profits and Progenics Pharma debt. Progenics Pharma cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Progenics Pharma had cash and cash equivalents of $138.9M at the beginning of the quarter and $87.39M at quarter end for 2018 Q1. The cash from operating activities for Progenics Pharma is $ 2018 Q1, which saw an increase from previous quarter.

View and download details of Progenics Pharma cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Net Income Cash Flow
-13.42M-51.01M-48.34M-32.99M-16.36M10.73M17.95M-18.33M-12.67M-39.11M
Depreciation Depletion Amortization Cash-Flow-1.12M---2.07M1.86M1.49M--
Net Increase (Decrease) in Assets Liabilities-3.02M--0.07M2.17M-6.22M4.37M3.27M3.29M-5.99M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net1.91M-4.44M6.6M4.9M2.53M-3.06M2.05M-4.41M
Net Cash from (used by) Operating Activities
-14.25M-53.62M-40.98M-25.37M-12.74M19.2M27.25M-11.5M-7.96M-40.13M
Increase (Decrease) in Prop Plant And Equipment-0.01M-0.23M-0.22M-0.2M-0.11M-3.93M-2.92M-2.42M-0.49M-0.32M
Acquisition Disposition of Subsidiaires----------6.2M
Increase (Decrease) in Investments----------
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
-0.01M-0.23M-0.22M-0.2M-0.11M-3.93M-2.92M-2.42M-0.49M-6.52M
Issuance (Purchase) of Equity Shares9.52M5.49M---1.34M---1.73M
Issuance (Repayment) of Debt Securities-----48.65M----
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities------0.36M----0.29M
Net Cash from (used by) Financing Activities
9.52M5.51M---49.62M---1.44M
Effect of Exchange Rate Changes on Cash-0.01M-----0.08M-0.05M-0.04M--
Net Change in Cash & Cash Equivalents
-4.76M-48.26M-40.63M-24.95M-12.6M64.8M24.79M-13.95M-8.42M-45.19M
Cash & Equivalents at Beginning of Year138.9M74.1M119.3M65.86M58.83M70.1M47.91M90.9M56.18M10.42M
Cash & Equivalents at Year End87.39M90.64M98.27M113.95M126.3M138.9M98.89M60.14M65.67M74.1M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Progenics Pharma stock comparison chart provides an easy way to compare the stock price with peers along with details of Progenics Pharma stock price history.
The statement of cash flows can be categorized into the following main sections:

  • Progenics Pharma saw a positive change in Net Change in Cash and Cash Equivalents of $-4.76M till 2018 Q1. Apart from the Progenics Pharma stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Progenics Pharma decreased its cash from operating activities to $-14.25M till 2018 Q1. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $-0.01M for PGNX till last quarter 2018 Q1 report.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $9.52M for Progenics Pharma. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Progenics Pharma Cash Flow

Quarterly Cash Flow Statements For Progenics Pharmaceuticals, Inc. Peers

Johnson & Johnson cash flow, Synergy Pharma cash flow, Valeant cash flow, Voyager Therapeutics cash flow